Organon & Co
OGN
Company Profile
Business description
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Contact
30 Hudson Street
Floor 33
Jersey CityNJ07302
USAT: +1 551 430-6900
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
10,000
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.30 | 50.20 | 0.55% |
| CAC 40 | 8,358.76 | 3.33 | -0.04% |
| DAX 40 | 25,405.34 | 143.70 | 0.57% |
| Dow JONES (US) | 49,590.20 | 86.13 | 0.17% |
| FTSE 100 | 10,140.70 | 16.10 | 0.16% |
| HKSE | 26,953.90 | 345.42 | 1.30% |
| NASDAQ | 23,733.90 | 62.56 | 0.26% |
| Nikkei 225 | 53,540.60 | 1,600.71 | 3.08% |
| NZX 50 Index | 13,654.07 | 29.22 | -0.21% |
| S&P 500 | 6,977.27 | 10.99 | 0.16% |
| S&P/ASX 200 | 8,847.50 | 56.20 | 0.64% |
| SSE Composite Index | 4,168.16 | 2.87 | 0.07% |